Effects of a Clinical Pharmacist Service on Health-related Quality of Life

This study has been completed.
Information provided by (Responsible Party):
Susanna Wallerstedt, Sahlgrenska University Hospital, Sweden
ClinicalTrials.gov Identifier:
First received: November 18, 2009
Last updated: November 17, 2015
Last verified: November 2015
The aim of the present study is to evaluate effects of a clinical pharmacist service on health-related quality of life and prescribing of drugs.

Condition Intervention
Quality of Life
Other: Pharmacist service

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Effects of a Clinical Pharmacist Service on Health-related Quality of Life

Further study details as provided by Sahlgrenska University Hospital, Sweden:

Primary Outcome Measures:
  • Health-related quality of life [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Prescribing of drugs [ Time Frame: Discharge from hospital ] [ Designated as safety issue: No ]

Enrollment: 400
Study Start Date: September 2007
Study Completion Date: July 2011
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Pharmacist service,
The pharmacist service consists of medication review, drug treatment discussion with the patient, and a medication report.
Other: Pharmacist service
Medication Review, medication report
No Intervention: Control
Usual care

Detailed Description:
A randomized controlled trial is performed in two internal medicine wards at Sahlgrenska University Hospital, Göteborg, Sweden.

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients admitted to the wards during week days after decision of a ward physician or nurse if the medical condition allows inclusion

Exclusion Criteria:

  • Exclusion criteria are poor Swedish language and planned discharge before the intervention can be performed.
  • Patients transferred to wards not belonging to the department of medicine or other hospitals during the hospital stay are also excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01016301

Sahlgrenska University Hospital
Mölndal, Sweden, 431 80
Sponsors and Collaborators
Sahlgrenska University Hospital, Sweden
Principal Investigator: Susanna Wallerstedt, MD, Ass Prof Sahlgrenska University Hospital, Sweden
  More Information

Responsible Party: Susanna Wallerstedt, MD, PhD, Sahlgrenska University Hospital, Sweden
ClinicalTrials.gov Identifier: NCT01016301     History of Changes
Other Study ID Numbers: CPS1
Study First Received: November 18, 2009
Last Updated: November 17, 2015
Health Authority: Sweden: Regional Ethical Review Board

ClinicalTrials.gov processed this record on November 25, 2015